## PLENARY DIALOGUE – 6 SEPTEMBER 2016
### MEDICAL DEVICE & BIOPHARMACEUTICAL SECTORS
The Westin Hotel & Convention Center, Las Begonias 450, San Isidro, Lima – Peru

<table>
<thead>
<tr>
<th>TIME</th>
<th>PROGRAM</th>
</tr>
</thead>
</table>
| 08:00-09:00| Arrival, Registration & Escorted to Seats – Limatambo One & Two, The Westin Lima  
Note: Attendees to arrive/seated by 8:30. Coffee/Refreshments in Terraza Merino Reyna. |
| 09:00-09:45| OPENING CEREMONY  
Facilitating Trans-Pacific Collaboration to Strengthen Ethical Business Practices  
Introductory Remarks: John Andersen, Chair, APEC SME Working Group  
Deputy Assistant Secretary for the Western Hemisphere, U.S. Department of Commerce  
Keynote Remarks: Dr. Patricia García Funegra, Minister of Health of Peru  
Presentation of the 2016 APEC Business Ethics for SMEs Lighthouse Award  
Emcee: Ms. Lynn Costa, Project Overseer, Business Ethics for APEC SMEs Initiative |
| 09:45-10:00| SIGNING CEREMONY  
Peru Consensus Framework for Multi-Stakeholder Ethical Collaboration in the Medical Device and Biopharmaceutical Sectors  
Ms. Lynn Costa, Project Overseer, Business Ethics for APEC SMEs Initiative  
Ms. Rocio Delgado, DIGEMID, Ministry of Health |
| 10:00-10:15| Official Photograph – Full Plenary Dialogue |
| 10:15-10:30| Regional Progress Report  
• Andrew Blasi, C&M International |
| 10:30-11:00| Networking Coffee / Tea Break – Terraza Merino Reyna |
| 11:00-13:00| Progress Dialogue by APEC Economies (3 Minute Updates + 3 Minute Q&A - Per Economy)  
Principals from each industry association, health care professional group, patient organization, government agency, and civil society body will offer brief verbal updates on:  
• Code of Ethics Status – Adoption, Implementation, Revisions  
• Status of Nanjing Declaration Implementation & Multi-Stakeholder Collaborations  
• Opportunities and Challenges: Overview and Outstanding Questions  
Session Chair: Datuk Hafsah Hashim, CEO, SME Corporation Malaysia |
**Networking Lunch Break – Limatambo Three, The Westin Lima**

**14:00-15:00**  
**Dialogue Session One:**  
**Designing & Launching Multi-Stakeholder Ethical Collaborations**  
- **Scene-Setting Remarks:** Ms. Maria Lourdes C. Santiago, Deputy Director-General, Philippines Food and Drug Administration  
- **Session Chair:** Mr. Russell Williams, Immediate Past Chair, APEC Biopharm WG on Ethics  
- **Key Consideration(s):** How can economies achieve universal launch of Multi-Stakeholder Ethical Collaborations by 2020 as advised by APEC Ministers? How can APEC support economies and facilitate the active participation of relevant industry and non-industry stakeholders? How can economies ensure the unique best practices within the medical device and biopharmaceutical sectors are reflected through such collaborations?

**15:00-16:00**  
**Dialogue Session Two:**  
**Promoting Strong Ethical Business Practices with Distributors / Third Party Intermediaries**  
- **Scene-Setting Remarks:** Ms. Bronwen Taylor, Vice President, Compliance and Risk Management, Stryker Corporation  
- **Session Chair:** Ms. Faye Sumner, Chief Executive Officer, Medical Technology Association of New Zealand (MTANZ)  
- **Key Consideration(s):** Should APEC pursue the development of best practice principles on promoting ethical business practices with third party intermediaries?

**16:00-16:30**  
**Networking Coffee / Tea Break – Terraza Merino Reyna**

**16:30-16:45**  
**Readout and Endorsement of Dialogue Recommendations**  
- Ms. Patricia Wu, C&M International

**16:45-17:30**  
**Global Showcase Session:**  
**Models to Actualize Multi-Stakeholder Ethical Collaborations**  
**Emcee:** Mr. Andrew Blasi, C&M International  
**Note:** Remarks only – PowerPoint slides are limited to information graphics.  
- **Ensuring an Inclusive and Consultative Approach (5 Mins)**  
  Dr. Kenneth Hartigan-Go, Vice President, Philippine College of Physicians  
  & Former Undersecretary of Health, Office for Health Regulation (The Philippines)  
- **Harmonizing & Sustaining One Code of Ethics for Multiple Industry Groups (5 Mins)**  
  Dr. Juan Francisco Millán Soberanes, Director, CETIFARMA (Mexico)  
- **Novel Strategies for Code of Ethics and Capacity-Building Collaboration between Industry Associations and Health Care Professional Bodies (5 Mins)**  
  Dr. Andreas Loeffer, President, Australian Orthopaedic Association  
- **Digital Strategies to Strengthen Ethical Practices for Third Party Intermediaries (5 Mins)**  
  Dr. Sergio Alcântara Madeira, Technical Director, ABRAIDI (Brazil)  
- **Assuring Ethical Collaborations between Industry and Patient Organizations (5 Mins)**  
  Ms. Leanne Wells, Chief Executive Officer, Consumer Health Forum of Australia
### Closing Session

- **Closing Remarks:**
  Ms. Melissa Stapleton Barnes, Senior Vice President, Enterprise Risk Management and Chief Ethics and Compliance Officer / Executive Committee, Eli Lilly and Company

- **Announcement of 2017 APEC Business Ethics for SMEs Forum:**
  Mr. To Hoai Nam, International Cooperation Division, Agency for Enterprise Development, Ministry of Planning and Investment (Viet Nam)

- **Final Takeaways:**
  Ms. Lynn Costa, Project Overseer, Business Ethics for APEC SMEs Initiative (The United States)

### Cross-Border Dialogues

**Emcee:** Ms. Kate Hamann, Partner, Pierce Atwood LLP / Former International Policy Counsel, U.S. Department of Justice

- **Economy Groups:**
  - **Group A:** Peru, Indonesia, Malaysia, Mexico, The United States
    - Kate Hamann to facilitate Group A discussion
  - **Group B:** Australia & The Philippines
  - **Group C:** China, Canada, & Hong Kong, China
  - **Group D:** Viet Nam, Thailand & Japan
  - **Group E:** Chile, Brazil, Colombia, New Zealand & Korea
  - **Note:** All economies not listed may select a preferred group of their choice. Groups B, C, D, and E to self-appoint discussion facilitator after convening at their station. The facilitator will submit key takeaways to Project Overseer.

- **Key Consideration(s):** How can paired economies enhance bilateral cooperation to strengthen ethical business practices in their respective medical device and biopharmaceutical sectors? What unique experiences and lessons learned are transferable between paired economies?